FDA says breast cancer drug Avastin did not extend lives

FDA says breast cancer drug Avastin did not extend lives
WASHINGTON — Federal health scientists say follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential halt in sales. The Food and Drug Administration approved Roche’s blockbuster Avastin in 2008 based on early-stage trials showing …